Results 151 to 160 of about 44,617 (246)

Complex Aortic Plaques and Polycythemia Vera Presenting as Blue Toe Syndrome Without Peripheral Arterial Disease. [PDF]

JACC Case Rep
Chebrolu S, O'Connor S, Doherty S, Aggarwal A, Rangel MO.   +4 more
europepmc   +1 more source

Differences in prevalence arising from reference values for physiological and laboratory measurements used in studies of Tibetan highlanders and differences in study populations between the two studies. [PDF]

J Physiol Anthropol
Arima H, Koirala S, Nishimura T.
europepmc   +1 more source

DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations. [PDF]

Ann Hematol
Arafat AMA, Ghaffar HAA, Khallaf AM, Younes SAM, Morad MA, Mahgoub SMA.   +5 more
europepmc   +1 more source

Clinical and disease characteristics from REVEAL at time of enrollment (baseline): Prospective observational study of patients with polycythemia vera in the United States [PDF]

, 2018
Boccia, Ralph V, Colucci, Philomena, Grunwald, Michael R, Mesa, Ruben, Oh, Stephen T, Paranagama, Dilan, Parasuraman, Shreekant, Stein, Brady L   +7 more
core   +1 more source

Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution. [PDF]

Cureus
Ahmad CM, Kastle RA, Zargarian L, Sawalha Y, Dalia S.   +4 more
europepmc   +1 more source

Washington University Medical Alumni Quarterly, July 1944 [PDF]

, 1944

core   +1 more source

Polycythemia caused by erythropoietin‐producing hemangiosarcoma

eJHaem
Osamu Imataki, Makiko Uemura
doaj   +1 more source

Tofacitinib Use in a Patient With Rheumatoid Arthritis and Polycythemia Vera: A Case Report. [PDF]

Clin Case Rep
Bogojevic M, Medjedovic R, Markovic M, Bakic N, Pravilovic Lutovac D.   +4 more
europepmc   +1 more source

Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97). [PDF]

Front Oncol
Felser S, Koeppel M, Kuehl R, le Coutre P, Al-Ali HK, Schulze S, Muegge LO, Bormann J, Geissler J, Dadgar A, Junghanss C, Ulbricht S.   +11 more
europepmc   +1 more source

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control. [PDF]

Ther Adv Hematol
Harrison CN, Kiladjian JJ, Hamer-Maansson JE, Naim A, Palandri F, Passamonti F.   +5 more
europepmc   +1 more source